Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)

被引：109

作者：

von Minckwitz, G. ^{[1
,2
]}

Loibl, S. ^{[1
]}

Untch, M. ^{[3
]}

Eidtmann, H. ^{[4
]}

Rezai, M. ^{[5
]}

Fasching, P. A. ^{[6
]}

Tesch, H. ^{[7
]}

Eggemann, H. ^{[8
]}

Schrader, I. ^{[9
]}

Kittel, K. ^{[10
]}

Hanusch, C. ^{[11
]}

Huober, J. ^{[12
]}

Solbach, C. ^{[2
]}

Jackisch, C. ^{[13
]}

Kunz, G. ^{[14
]}

Blohmer, J. U. ^{[15
]}

Hauschild, M. ^{[16
]}

Fehm, T. ^{[17
]}

Nekljudova, V. ^{[1
]}

Gerber, B. ^{[18
]}

机构：

[1] German Breast Grp, Neu Isenburg, Germany

[2] Univ Hosp, Dept Obstet & Gynaecol, Frankfurt, Germany

[3] Klinikum Berlin, Dept Obstet & Gynaecol, Berlin, Germany

[4] Univ Hosp, Dept Obstet & Gynaecol, Kiel, Germany

[5] Luisenkrankenhaus, Breast Ctr, Dusseldorf, Germany

[6] Univ Hosp, Dept Gynecol & Obstet, Erlangen, Germany

[7] Chop GmbH, Dept Canc Med, Frankfurt, Germany

[8] Univ Hosp, Dept Obstet & Gynaecol, Magdeburg, Germany

[9] Henriettenstiftung, Dept Obstet & Gynaecol, Hannover, Germany

[10] Praxisklinik, Dept Obstet & Gynaecol, Berlin, Germany

[11] Rot Kreuz Klinikum, Dept Obstet & Gynaecol, Munich, Germany

[12] Univ Hosp, Dept Obstet & Gynaecol, Ulm, Germany

[13] Sana Klinikum, Dept Obstet & Gynaecol, Offenbach, Germany

[14] St Johannes Hosp, Dept Obstet & Gynaecol, Dortmund, Germany

[15] St Gertrauden Hosp, Dept Obstet & Gynaecol, Berlin, Germany

[16] Hosp Rheinfelden, Dept Obstet & Gynaecol, Rheinfelden, Germany

[17] Univ Tubingen Hosp, Dept Obstet & Gynaecol, Tubingen, Germany

[18] Univ Hosp, Dept Obstet & Gynaecol, Rostock, Germany

来源：

ANNALS OF ONCOLOGY | 2014年 / 25卷 / 12期

关键词：

bevacizumab; everolimus; neoadjuvant chemotherapy; disease-free survival; overall survival; TAXANE-BASED CHEMOTHERAPY; III RANDOMIZED GEPARTRIO; PHASE-3; TRIAL; GEPARQUINTO; TRASTUZUMAB; THERAPY;

D O I：

10.1093/annonc/mdu455

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The GeparQuinto study showed that adding bevacizumab to 24 weeks of anthracycline-taxane-based neoadjuvant chemotherapy increases pathological complete response (pCR) rates overall and specifically in patients with triple-negative breast cancer (TNBC). No difference in pCR rate was observed for adding everolimus to paclitaxel in nonearly responding patients. Here, we present disease-free (DFS) and overall survival (OS) analyses. Patients and methods: Patients (n = 1948) with HER2-negative tumors of a median tumor size of 4 cm were randomly assigned to neoadjuvant treatment with epirubicin/cyclophosphamide followed by docetaxel (EC-T) with or without eight infusions of bevacizumab every 3 weeks before surgery. Patients without clinical response to EC +/- Bevacizumab were randomized to 12 weekly cycles paclitaxel with or without everolimus 5 mg/day. To detect a hazard ratio (HR) of 0.75 (alpha = 0.05, beta = 0.8) 379 events had to be observed in the bevacizumab arms. Results: With a median follow-up of 3.8 years, 3-year DFS was 80.8% and 3-year OS was 89.7%. Outcome was not different for patients receiving bevacizumab (HR 1.03; P = 0.784 for DFS and HR 0.974; P = 0.842 for OS) compared with patients receiving chemotherapy alone. Patients with TNBC similarly showed no improvement in DFS (HR = 0.99; P = 0.941) and OS (HR = 1.02; P = 0.891) when treated with bevacizumab. No other predefined subgroup (HR+/HER2-; locally advanced (cT4 or cN3) or not; cT1-3 or cT4; pCR or not) showed a significant benefit. No difference in DFS (HR 0.997; P = 0.987) and OS (HR 1.11; P = 0.658) was observed for nonearly responding patients receiving paclitaxel with or without everolimus overall as well as in subgroups. Conclusions: Long-term results, in opposite to the results of pCR, do not support the neoadjuvant use of bevacizumab in addition to an anthracycline-taxane-based chemotherapy or everolimus in addition to paclitaxel for nonearly responding patients.

引用

页码：2363 / 2372

页数：10

共 15 条

[1] Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial [J].

Cameron, David ;

Brown, Julia ;

Dent, Rebecca ;

Jackisch, Christian ;

Mackey, John ;

Pivot, Xavier ;

Steger, Guenther G. ;

Suter, Thomas M. ;

Toi, Masakazu ;

Parmar, Mahesh ;

Laeufle, Rita ;

Im, Young-Hyuck ;

Romieu, Gilles ;

Harvey, Vernon ;

Lipatov, Oleg ;

Pienkowski, Tadeusz ;

Cottu, Paul ;

Chan, Arlene ;

Im, Seock-Ah ;

Hall, Peter S. ;

Bubuteishvili-Pacaud, Lida ;

Henschel, Volkmar ;

Deurloo, Regula J. ;

Pallaud, Celine ;

Bell, Richard .

LANCET ONCOLOGY, 2013, 14 (10) :933-942

[2] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].

Cortazar, Patricia ;

Zhang, Lijun ;

Untch, Michael ;

Mehta, Keyur ;

Costantino, Joseph P. ;

Wolmark, Norman ;

Bonnefoi, Herve ;

Cameron, David ;

Gianni, Luca ;

Valagussa, Pinuccia ;

Swain, Sandra M. ;

Prowell, Tatiana ;

Loibl, Sibylle ;

Wickerham, D. Lawrence ;

Bogaerts, Jan ;

Baselga, Jose ;

Perou, Charles ;

Blumenthal, Gideon ;

Blohmer, Jens ;

Mamounas, Eleftherios P. ;

Bergh, Jonas ;

Semiglazov, Vladimir ;

Justice, Robert ;

Eidtmann, Holger ;

Paik, Soonmyung ;

Piccart, Martine ;

Sridhara, Rajeshwari ;

Fasching, Peter A. ;

Slaets, Leen ;

Tang, Shenghui ;

Gerber, Bernd ;

Geyer, Charles E., Jr. ;

Pazdur, Richard ;

Ditsch, Nina ;

Rastogi, Priya ;

Eiermann, Wolfgang ;

von Minckwitz, Gunter .

LANCET, 2014, 384 (9938) :164-172

[3] Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial [J].

de Gramont, Aimery ;

Van Cutsem, Eric ;

Schmoll, Hans-Joachim ;

Tabernero, Josep ;

Clarke, Stephen ;

Moore, Malcolm J. ;

Cunningham, David ;

Cartwright, Thomas H. ;

Hecht, J. Randolph ;

Rivera, Fernando ;

Im, Seock-Ah ;

Bodoky, Gyoergy ;

Salazar, Ramon ;

Maindrault-Goebel, Frederique ;

Shacham-Shmueli, Einat ;

Bajetta, Emilio ;

Makrutzki, Martina ;

Shang, Aijing ;

Andre, Thierry ;

Hoff, Paulo M. .

LANCET ONCOLOGY, 2012, 13 (12) :1225-1233

[4] Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44) [J].

Gerber, B. ;

Loibl, S. ;

Eidtmann, H. ;

Rezai, M. ;

Fasching, P. A. ;

Tesch, H. ;

Eggemann, H. ;

Schrader, I. ;

Kittel, K. ;

Hanusch, C. ;

Kreienberg, R. ;

Solbach, C. ;

Jackisch, C. ;

Kunz, G. ;

Blohmer, J. U. ;

Huober, J. ;

Hauschild, M. ;

Nekljudova, V. ;

Untch, M. ;

von Minckwitz, G. .

ANNALS OF ONCOLOGY, 2013, 24 (12) :2978-2984

[5] Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort [J].

Gianni, Luca ;

Eiermann, Wolfgang ;

Semiglazov, Vladimir ;

Lluch, Ana ;

Tjulandin, Sergei ;

Zambetti, Milvia ;

Moliterni, Angela ;

Vazquez, Federico ;

Byakhov, Mikhail J. ;

Lichinitser, Mikhail ;

Climent, Miguel Angel ;

Ciruelos, Eva ;

Ojeda, Belen ;

Mansutti, Mauro ;

Bozhok, Alla ;

Magazzu, Domenico ;

Heinzmann, Dominik ;

Steinseifer, Jutta ;

Valagussa, Pinuccia ;

Baselga, Jose .

LANCET ONCOLOGY, 2014, 15 (06) :640-647

[6] Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system [J].

Hudis, Clifford A. ;

Barlow, William E. ;

Costantino, Joseph P. ;

Gray, Robert J. ;

Pritchard, Kathleen I. ;

Chapman, Judith-Anne W. ;

Sparano, Joseph A. ;

Hunsberger, Sally ;

Enos, Rebecca A. ;

Gelber, Richard D. ;

Zujewski, Jo Anne .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) :2127-2132

[7] Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - Results of the randomised GeparQuinto study (GBG 44) [J].

Huober, Jens ;

Fasching, Peter A. ;

Hanusch, Claus ;

Rezai, Mahdi ;

Eidtmann, Holger ;

Kittel, Kornelia ;

Hilfrich, Joern ;

Schwedler, Kathrin ;

Blohmer, Jens-Uwe ;

Tesch, Hans ;

Gerber, Bernd ;

Hoess, Cornelia ;

Kuemmel, Sherko ;

Mau, Christine ;

Jackisch, Christian ;

Khandan, Fariba ;

Costa, Serban Dan ;

Krabisch, Petra ;

Loibl, Sibylle ;

Nekljudova, Valentina ;

Untch, Michael ;

von Minckwitz, Gunter .

EUROPEAN JOURNAL OF CANCER, 2013, 49 (10) :2284-2293

[8] Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer [J].

Kaufmann, Manfred ;

von Minckwitz, Gunter ;

Mamounas, Elefhterios P. ;

Cameron, David ;

Carey, Lisa A. ;

Cristofanilli, Massimo ;

Denkert, Carsten ;

Eiermann, Wolfgang ;

Gnant, Michael ;

Harris, Jay R. ;

Karn, Thomas ;

Liedtke, Cornelia ;

Mauri, Davide ;

Rouzier, Roman ;

Ruckhaeberle, Eugen ;

Semiglazov, Vladimir ;

Symmans, W. Fraser ;

Tutt, Andrew ;

Pusztai, Lajos .

ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (05) :1508-1516

[9]

MILLER K, 2014, J CLIN ONCOL SUPPL, V32

[10] Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial [J].

Untch, Michael ;

Loibl, Sibylle ;

Bischoff, Joachim ;

Eidtmann, Holger ;

Kaufmann, Manfred ;

Blohmer, Jens-Uwe ;

Hilfrich, Joern ;

Strumberg, Dirk ;

Fasching, Peter A. ;

Kreienberg, Rolf ;

Tesch, Hans ;

Hanusch, Claus ;

Gerber, Bernd ;

Rezai, Mahdi ;

Jackisch, Christian ;

Huober, Jens ;

Kuehn, Thorsten ;

Nekljudova, Valentina ;

von Minckwitz, Gunter .

LANCET ONCOLOGY, 2012, 13 (02) :135-144

← 1 2 →